Robert Harrington to Thrombolytic Therapy
This is a "connection" page, showing publications Robert Harrington has written about Thrombolytic Therapy.
Connection Strength
1.962
-
Women, acute ischemic heart disease, and antithrombotic therapy: challenges and opportunities. Circulation. 2007 Jun 05; 115(22):2796-8.
Score: 0.249
-
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. Am Heart J. 2006 Feb; 151(2):316-22.
Score: 0.227
-
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006 Feb 21; 47(4):809-16.
Score: 0.227
-
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. Am J Med. 2004 Jan 15; 116(2):119-29.
Score: 0.197
-
Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022 Feb 15; 327(7):662-675.
Score: 0.173
-
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. Am Heart J. 2019 09; 215:106-113.
Score: 0.142
-
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018 07; 201:124-135.
Score: 0.132
-
Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. Am Heart J. 2018 07; 201:103-110.
Score: 0.132
-
Noninvasive, medical management for non-ST-elevation acute coronary syndromes. Am Heart J. 2008 Mar; 155(3):397-407.
Score: 0.066
-
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation. 2008 Jan 15; 117(2):192-9.
Score: 0.065
-
Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. Am J Cardiol. 2007 Mar 15; 99(6):793-6.
Score: 0.061
-
Platelet inhibitor therapy for patients with cardiovascular disease: looking toward the future. Curr Hematol Rep. 2005 Sep; 4(5):397-404.
Score: 0.055
-
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol. 2005 Mar 01; 95(5):611-4.
Score: 0.053
-
Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol. 2005 Feb 01; 95(3):383-6.
Score: 0.053
-
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):549S-575S.
Score: 0.051
-
Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004 Jun 01; 93(11):1362-7, A5-6.
Score: 0.051
-
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007 Dec 04; 116(23):2669-77.
Score: 0.016
-
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003 Oct; 146(4):628-34.
Score: 0.012